
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2140187/publications.pdf Version: 2024-02-01



Ριτλ Μιιρρι

#	Article	IF	CITATIONS
1	Machine Learning and Antibiotic Management. Antibiotics, 2022, 11, 304.	3.7	2
2	Cefiderocol for Severe Carbapenem-Resistant A. baumannii Pneumonia: Towards the Comprehension of Its Place in Therapy. Antibiotics, 2022, 11, 3.	3.7	20
3	Daptomycin-based aminoglycoside-sparing therapy for streptococcal endocarditis: a retrospective multicenter study. Journal of Chemotherapy, 2021, 33, 435-439.	1.5	2
4	Attitudes towards Anti-SARS-CoV2 Vaccination among Healthcare Workers: Results from a National Survey in Italy. Viruses, 2021, 13, 371.	3.3	132
5	The Role of Early Procalcitonin Determination in the Emergency Departiment in Adults Hospitalized with Fever. Medicina (Lithuania), 2021, 57, 179.	2.0	6
6	Post-Prescription Audit Plus Beta-D-Glucan Assessment Decrease Echinocandin Use in People with Suspected Invasive Candidiasis. Medicina (Lithuania), 2021, 57, 656.	2.0	4
7	Prognostic Role of Serum Procalcitonin Measurement in Adult Patients Admitted to the Emergency Department with Fever. Antibiotics, 2021, 10, 788.	3.7	6
8	Impact of SARS-CoV-2 Epidemic on Antimicrobial Resistance: A Literature Review. Viruses, 2021, 13, 2110.	3.3	65
9	Procalcitonin, white blood cell count and C-reactive protein as predictors of S. aureus infection and mortality in infective endocarditis. International Journal of Cardiology, 2020, 301, 190-194.	1.7	22
10	Reduced utility of early procalcitonin and blood culture determination in patients with febrile urinary tract infections in the emergency department. Internal and Emergency Medicine, 2020, 15, 119-125.	2.0	11
11	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. Journal of Antimicrobial Chemotherapy, 2020, 75, 628-639.	3.0	7
12	Comparative performance evaluation of Wako β-glucan test and Fungitell assay for the diagnosis of invasive fungal diseases. PLoS ONE, 2020, 15, e0236095.	2.5	20
13	Antibiotic appropriateness and adherence to local guidelines in perioperative prophylaxis: results from an antimicrobial stewardship intervention. Antimicrobial Resistance and Infection Control, 2020, 9, 164.	4.1	20
14	Social media as a tool for scientific updating at the time of COVID pandemic: Results from a national survey in Italy. PLoS ONE, 2020, 15, e0238414.	2.5	16
15	Early procalcitonin determination in the emergency department and clinical outcome of community-acquired pneumonia in old and oldest old patients. European Journal of Internal Medicine, 2020, 79, 51-57.	2.2	6
16	A proposal for a comprehensive approach to infections across the surgical pathway. World Journal of Emergency Surgery, 2020, 15, 13.	5.0	15
17	Efficacy and safety of levofloxacin as a treatment for complicated urinary tract infections and pyelonephritis. Expert Opinion on Pharmacotherapy, 2020, 21, 637-644.	1.8	15
18	Management of mycotic aorto-iliac aneurysms: a 30-year monocentric experience. European Review for Medical and Pharmacological Sciences, 2020, 24, 3274-3281.	0.7	2

#	Article	IF	CITATIONS
19	Performance evaluation of the (1,3)-β-D-glucan detection assay in non-intensive care unit adult patients. Infection and Drug Resistance, 2019, Volume 12, 19-24.	2.7	11
20	Risk factors for recurrence in patients with Clostridium difficile infection due to 027 and non-027 ribotypes. Clinical Microbiology and Infection, 2019, 25, 474-480.	6.0	15
21	Comparison of antimicrobial stewardship programmes in acute-care hospitals in four European countries: A cross-sectional survey. International Journal of Antimicrobial Agents, 2019, 54, 338-345.	2.5	8
22	<direct eazyplex<sup="" of="" use="">® SuperBug CRE assay from positive blood cultures in conjunction with inpatient infectious disease consulting for timely appropriate antimicrobial therapy in Escherichia coli and Klebsiella pneumoniae bloodstream infections. Infection and Drug Resistance, 2019, Volume 12, 1055-1062.</direct>	2.7	11
23	Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With Recurrent <i>Clostridioides difficile</i> Infection Treated With Fecal Microbiota Transplantation or Antibiotics. Annals of Internal Medicine, 2019, 171, 695.	3.9	81
24	Use of procalcitonin as a tool for antibiotic stewardship. Future Microbiology, 2019, 14, 77-79.	2.0	0
25	The role of procalcitonin outside of the Intensive Care Unit (ICU): a multidisciplinary approach. European Review for Medical and Pharmacological Sciences, 2019, 23, 2978-2985.	0.7	1
26	IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines. Clinical Infectious Diseases, 2018, 66, 1815-1816.	5.8	5
27	Systematic clinical management of patients with candidemia improves survival. Journal of Infection, 2018, 77, 145-150.	3.3	13
28	A 72-h intervention for improvement of the rate of optimal antibiotic therapy in patients with bloodstream infections. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 167-173.	2.9	11
29	Trimethoprim–sulfamethoxazole therapy for patients with carbapenemase-producing Klebsiella pneumoniae infections: retrospective single-center case series. Infection, 2017, 45, 209-213.	4.7	21
30	Antibiotic stewardship from toolkit to local implementation: the â€~gutta cavat lapidem' strategy. Future Microbiology, 2017, 12, 935-938.	2.0	3
31	Validation of a self-reported HIV symptoms list: the ISS-HIV symptoms scale. AIDS Research and Therapy, 2016, 13, 18.	1.7	6
32	Liver Resection for Primary Intrahepatic Stones: Focus on Postoperative Infectious Complications. World Journal of Surgery, 2016, 40, 433-439.	1.6	7
33	Nursing home residence is associated with spread of Clostridium difficile ribotype 027 in central Italy. Journal of Hospital Infection, 2016, 94, 201-203.	2.9	4
34	Impact of antibiotic stewardship on perioperative antimicrobial prophylaxis. International Journal for Quality in Health Care, 2016, 28, 502-507.	1.8	19
35	Host and disease factors are associated with cognitive function in European <scp>HIV</scp> â€infected adults prior to initiation of antiretroviral therapy. HIV Medicine, 2016, 17, 471-478.	2.2	7
36	Initial antifungal strategy does not correlate with mortality in patients with candidemia. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 187-193.	2.9	22

#	Article	IF	CITATIONS
37	Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection. Infectious Diseases, 2016, 48, 48-55.	2.8	5
38	Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. Journal of Antimicrobial Chemotherapy, 2016, 71, 1056-1062.	3.0	22
39	Resource-saving advice from an infectious diseases specialist team in a large university hospital: an exportable model?. Future Microbiology, 2015, 10, 15-20.	2.0	8
40	Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study). Scandinavian Journal of Infectious Diseases, 2014, 46, 34-45.	1.5	23
41	Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment) Tj ETQq1 1 0.7843	14 rg81 /Ov	verlock 10 T
42	Revised Central Nervous System Neuropenetration-Effectiveness Score is Associated with Cognitive Disorders in HIV-Infected Patients with Controlled Plasma Viraemia. Antiviral Therapy, 2013, 18, 153-160.	1.0	52
43	The Challenge of Identifying Resistant-Organism Pneumonia in the Emergency Department: Still Navigating on the Erie Canal?. Clinical Infectious Diseases, 2012, 54, 199-201.	5.8	2
44	Management of Recurrent Cutaneous Abscesses During Therapy With Infliximab. Clinical Therapeutics, 2011, 33, 1993-1996.	2.5	6
45	Physicians' knowledge of health-related quality of life and perception of its importance in daily clinical practice. Health and Quality of Life Outcomes, 2010, 8, 43.	2.4	24
46	Incidence of Malignancies in HIVâ€Infected Patients and Prognostic Role of Current CD4 Cell Count: Evidence from a Large Italian Cohort Study. Clinical Infectious Diseases, 2010, 50, 1316-1321.	5.8	56
47	Asymmetry of the Regimen Is Correlated to Self-Reported Suboptimal Adherence: Results From AdUCSC, a Cohort Study on Adherence in Italy. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 411-412.	2.1	11
48	Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma. Aids, 2010, 24, 2408-2412.	2.2	27
49	Rate and Predictors of Self-Chosen Drug Discontinuations in Highly Active Antiretroviral Therapy-Treated HIV-Positive Individuals. AIDS Patient Care and STDs, 2009, 23, 35-39.	2.5	8
50	Women Facing HIV. Key Question on Women with HIV Infection: Italian Consensus Workshop. Infection, 2009, 37, 168-178.	4.7	5
51	Self-Reported Sexual Dysfunction Is Frequent Among HIV-Infected Persons and Is Associated with Suboptimal Adherence to Antiretrovirals. AIDS Patient Care and STDs, 2008, 22, 291-299.	2.5	33
52	Severity of Lipodystrophy Is Associated with Decreased Health-Related Quality of Life. AIDS Patient Care and STDs, 2008, 22, 577-585.	2.5	41
53	Sexual dysfunction in HIV infection. Lancet, The, 2007, 369, 905-906.	13.7	19
54	Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura. Annals of Hematology, 2007, 86, 225-226.	1.8	23

#	Article	IF	CITATIONS
55	Sexual dysfunction in HIV-infected men: role of antiretroviral therapy, hypogonadism and lipodystrophy. Antiviral Therapy, 2007, 12, 1059-65.	1.0	15
56	Sexual Dysfunction in HIV-Infected Men: Role of Antiretroviral Therapy, Hypogonadism and Lipodystrophy. Antiviral Therapy, 2007, 12, 1059-1066.	1.0	54
57	Is "Once-Daily" Regimen a Key Strategy for Improving Adherence to Antiretroviral Regimens?. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 259-260.	2.1	7
58	ls Moderate HIV Viremia Associated With a Higher Risk of Clinical Progression in HIV-Infected People Treated With Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 23-30.	2.1	44
59	ISSQoL: A New Questionnaire for Evaluating the Quality of Life of People Living with HIV in the HAART Era*. Quality of Life Research, 2006, 15, 377-390.	3.1	27
60	Quality of Life and Body Image in the Assessment of Psychological Impact of Lipodystrophy: Validation of the Italian Version of Assessment of Body Change and Distress Questionnaire. Quality of Life Research, 2006, 15, 173-178.	3.1	46
61	Access to gynecological services and Papanicolau tests in HIV-infected Italian women: A questionnaire survey. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2006, 18, 376-378.	1.2	5
62	Interruption of Highly Active Antiretroviral Therapy in HIV Clinical Practice. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, 407-416.	2.1	46
63	Partnership of HIV-Infected Women and Health Status. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 39, 502-503.	2.1	0
64	Highly active antiretroviral therapy. BMJ: British Medical Journal, 2005, 330, 681-682.	2.3	3
65	Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART. International Journal of STD and AIDS, 2004, 15, 254-259.	1.1	84
66	Patient-reported and physician-estimated adherence to HAART. Journal of General Internal Medicine, 2004, 19, 1104-1110.	2.6	60
67	Depressive Symptoms, Neurocognitive Impairment, and Adherence to Highly Active Antiretroviral Therapy Among HIV-Infected Persons. Psychosomatics, 2004, 45, 394-402.	2.5	231
68	Relative Prognostic Value of Self-Reported Adherence and Plasma Nnrti/Pi Concentrations to Predict Virological Rebound in Patients Initially Responding to Haart. Antiviral Therapy, 2004, 9, 291-296.	1.0	32
69	Variable Prediction of Antiretroviral Treatment Outcome by Different Systems for Interpreting Genotypic Human Immunodeficiency Virus Type 1 Drug Resistance. Journal of Infectious Diseases, 2003, 187, 1934-1943.	4.0	96
70	Determinants of health-related quality of life in HIV-infected patients. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2003, 15, 581-590.	1.2	104
71	Neurocognitive Performance and Quality of Life in Patients with HIV Infection. AIDS Research and Human Retroviruses, 2003, 19, 643-652.	1.1	107
72	Access to Antiretroviral Treatment, Incidence of Sustained Therapy Interruptions, and Risk of Clinical Events According to Sex. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 184-190.	2.1	64

#	Article	IF	CITATIONS
73	Nonnucleoside Reverse Transcriptase Inhibitor-Containing Regimens Are Associated With Increased Satisfaction With Sexual Life. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 532-534.	2.1	5
74	Morphologic Alterations in HIV-Infected People with Lipodystrophy Are Associated with Good Adherence to HAART. HIV Clinical Trials, 2003, 4, 99-106.	2.0	38
75	Depression Is a Risk Factor for Suboptimal Adherence to Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, S136-S139.	2.1	238
76	Correlates and Predictors of Adherence to Highly Active Antiretroviral Therapy: Overview of Published Literature. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, S123-S127.	2.1	390
77	Physician Estimates of Adherence and the Patient-Physician Relationship as a Setting to Improve Adherence to Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, S158-S162.	2.1	55
78	Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). Aids, 2002, 16, 369-379.	2.2	189
79	Declining Tuberculosis and Drug Resistance Rate Among HIV-Positive Patients at an Italian Teaching Hospital in the Era of Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 546-547.	2.1	3
80	Adherence to Protease Inhibitors. Annals of Internal Medicine, 2001, 134, 625.	3.9	2
81	Incidence and Determinants of Bacterial Infections in HIV-Positive Patients Receiving Anti-Pneumocystis carinii/ Toxoplasma gondii Primary Prophylaxis Within a Randomized Clinical Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 49-55.	2.1	2
82	Incidence and Determinants of Bacterial Infections in HIV-Positive Patients Receiving Anti-Pneumocystis carinii/ Toxoplasma gondii Primary Prophylaxis Within a Randomized Clinical Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 49-55.	2.1	4
83	Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. Journal of NeuroVirology, 2001, 7, 323-328.	2.1	68
84	Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: Extended follow-up of an observational study. Journal of NeuroVirology, 2001, 7, 364-368.	2.1	64
85	Self-Reported Nonadherence with Antiretroviral Drugs Predicts Persistent Condition. HIV Clinical Trials, 2001, 2, 323-329.	2.0	31
86	Self-Reported Symptoms and Medication Side Effects Influence Adherence to Highly Active Antiretroviral Therapy in Persons With HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 445-449.	2.1	405
87	Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. Aids, 2001, 15, 1579-1581.	2.2	67
88	Patient-Reported Nonadherence to HAART Is Related to Protease Inhibitor Levels. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 123-128.	2.1	65
89	Circulating Levels andex VivoProduction of β-Chemokines, Interferon γ, and Interleukin 2 in Advanced Human Immunodeficiency Virus Type 1 Infection: The Effect of Protease Inhibitor Therapy. AIDS Research and Human Retroviruses, 2000, 16, 835-843.	1.1	12
90	Patient-Reported Nonadherence to HAART Is Related to Protease Inhibitor Levels. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 123-128.	2.1	120

#	Article	IF	CITATIONS
91	Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy. Aids, 2000, 14, F117-F121.	2.2	72
92	The Effect of Potent Antiretroviral Therapy and JC Virus Load in Cerebrospinal Fluid on Clinical Outcome of Patients with AIDSâ€Associated Progressive Multifocal Leukoencephalopathy. Journal of Infectious Diseases, 2000, 182, 1077-1083.	4.0	113
93	Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study. Aids, 2000, 14, 1655-1656.	2.2	11
94	Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study. Aids, 2000, 14, 1660-1662.	2.2	42
95	Clinical and Virological Monitoring During Treatment with Intrathecal Cytarabine in Patients with AIDSâ€Associated Progressive Multifocal Leukoencephalopathy. Clinical Infectious Diseases, 1999, 28, 624-628.	5.8	55
96	Definition and measurement of adherence to antiretroviral drugs in HIV-1-infected patients. Lancet, The, 1999, 353, 1974.	13.7	16
97	Intravenous Drug Use, Relationship With Providers, and Stage of HIV Disease Influence the Prescription Rates of Protease Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 22, 461.	2.1	23
98	Intravenous Drug Use, Relationship With Providers, and Stage of HIV Disease Influence the Prescription Rates of Protease Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 22, 461.	2.1	24
99	Changing Disease Patterns in Focal Brain Lesion-Causing Disorders in AIDS. Journal of Acquired Immune Deficiency Syndromes, 1998, 18, 365-371.	0.3	46
100	Disease-Related Factors Associated With Health-Related Quality of Life in People With Nonadvanced HIV Disease Assessed Using an Italian Version of the MOS-HIV Health Survey. Journal of Acquired Immune Deficiency Syndromes, 1997, 16, 350-356.	0.3	45
101	Low-dose dapsone, co-trimoxazole, and survival in Pneumocystis carinii primary prophylaxis. Aids, 1996, 10, 1046-1047.	2.2	1
102	Cognitive Impairment in Asymptomatic Stages of HIV Infection. European Neurology, 1996, 36, 125-133.	1.4	35
103	PCR detection of Toxoplasma gondii DNA in CSF for the differential diagnosis of AIDS-related focal brain lesions. Journal of Medical Microbiology, 1996, 45, 472-476.	1.8	72
104	Imbalance between Pneumocystis carinii cysts and trophozoites in bronchoalveolar lavage fluid from patients with pneumocystosis receiving prophylaxis. Journal of Medical Microbiology, 1996, 45, 146-148.	1.8	16
105	Karnofsky Performance Status and Assessment of Global Health Status. Journal of Acquired Immune Deficiency Syndromes, 1996, 13, 294.	0.3	18
106	Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Aids, 1995, 9, 1343-1350.	2.2	62
107	Fluconazole for Primary Prophylaxis of AIDS-associated Cryptococcosis: A Case-control Study. Scandinavian Journal of Infectious Diseases, 1995, 27, 235-237.	1.5	14
108	Presumptive Clinical Criteria Versus Endoscopy in the Diagnosis of Candida Esophagitis at Various HIV-1 Disease Stages. Endoscopy, 1995, 27, 371-376.	1.8	14

#	Article	IF	CITATIONS
109	Prognostic factors of early fatal outcome and long-term survival in patients with Pneumocystis carinii pneumonia and acquired immunodeficiency syndrome. European Journal of Epidemiology, 1993, 9, 183-189.	5.7	16
110	Primary central nervous system lymphoma and brain biopsy in AIDS. Lancet, The, 1993, 341, 1411-1412.	13.7	15
111	Failure of low-dose dapsone-pyrimethamine in primary prophylaxis of Pneumocystis carinii pneumonia. Lancet, The, 1992, 340, 788.	13.7	18
112	Evaluation of different staging systems for Kaposi's sarcoma in HIV-infected patients. Journal of Cancer Research and Clinical Oncology, 1992, 118, 635-636.	2.5	10